Literature DB >> 22674517

Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study.

Jasmohan S Bajaj1, Leroy R Thacker, Douglas M Heuman, Richard K Sterling, R Todd Stravitz, Arun J Sanyal, Velimir Luketic, Michael Fuchs, Ho Chong S Gilles, James B Wade.   

Abstract

Psychiatric disorders and medications may affect the cognitive performance of patients with cirrhosis and complicate the diagnosis and prediction of hepatic encephalopathy (HE). The aim of this study was to study the association of psychoactive medications with cognitive performance and their effects on the ability of tests to predict HE development in patients with cirrhosis referred for transplant evaluation. Cirrhosis details, psychiatric disorders, psychoactive medications, and any history of prior HE were recorded for patients with cirrhosis at 2 transplant centers. Patients were followed until the development of HE. Five cognitive tests--number connection test A (NCT-A), number connection test B, the digit symbol test (DST), the block design test, and the inhibitory control test (ICT)--were administered. A high lure score and a low ICT target score indicated poor performance. The cognitive performances of patients with psychiatric disorders/medications and patients without them were compared. A proportional hazards model was created with the time to HE as the outcome, and it was based on demographics, psychoactive medications, cirrhosis details, and individual cognitive scores. Patients with prior HE and patients without prior HE were then studied separately. One hundred fifty-five patients with a mean age of 57.5 ± 6.2 years and a mean Model for End-Stage Liver Disease (MELD) score of 15.1 ± 6.2 were included [prior HE, 48%; diabetes, 34%; selective serotonin reuptake inhibitors (SSRIs), 32%; opioids, 19%; and antipsychotics, 10%]. Prior HE and antipsychotics (but not opioids or diabetes) were associated with worse cognition. SSRI users had better NCT-A and DST performance. One hundred forty-eight patients were followed for a median of 182.5 days; 58 developed HE at a median of 99 days after inclusion. In the entire group, the model showed that prior HE (hazard ratio = 4.13), the MELD score (hazard ratio = 1.07), and a high lure score (hazard ratio = 1.04) decreased the time to HE, whereas the use of SSRIs (hazard ratio = 0.42), a high target score (hazard ratio = 0.95), and a high sodium level (hazard ratio = 0.89) increased the time to HE. For patients without prior HE, the MELD score (hazard ratio = 1.25) and lures (hazard ratio = 1.09) predicted the time to HE. Lures (hazard ratio = 1.03), targets (hazard ratio = 0.96), and sodium (hazard ratio = 0.87) were associated with the time to HE in patients with prior HE. In conclusion, cognitive tests (particularly the ICT) remain valid predictors of HE in the face of psychiatric diseases and medications. SSRI use is associated with better cognitive performance and a reduced likelihood of developing HE.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674517      PMCID: PMC3604696          DOI: 10.1002/lt.23484

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  43 in total

1.  An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia.

Authors:  P W Schofield; G Logroscino; H F Andrews; S Albert; Y Stern
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

2.  Improving the inhibitory control task to detect minimal hepatic encephalopathy.

Authors:  Piero Amodio; Lorenzo Ridola; Sami Schiff; Sara Montagnese; Chiara Pasquale; Silvia Nardelli; Ilaria Pentassuglio; Maria Trezza; Chiara Marzano; Cristiana Flaiban; Paolo Angeli; Giorgia Cona; Patrizia Bisiacchi; Angelo Gatta; Oliviero Riggio
Journal:  Gastroenterology       Date:  2010-05-11       Impact factor: 22.682

3.  Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder.

Authors:  Meryl A Butters; Rishi K Bhalla; Carmen Andreescu; Julie Loebach Wetherell; Rose Mantella; Amy E Begley; Eric J Lenze
Journal:  Br J Psychiatry       Date:  2011-07-04       Impact factor: 9.319

4.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Authors:  Cheryl L P Vigen; Wendy J Mack; Richard S E Keefe; Mary Sano; David L Sultzer; T Scott Stroup; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Pierre N Tariot; Ling Zheng; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

5.  Electroencephalography in patients with cirrhosis.

Authors:  Piergiorgio Marchetti; Costanza D'Avanzo; Raffaele Orsato; Sara Montagnese; Sami Schiff; Peter W Kaplan; Francesco Piccione; Carlo Merkel; Angelo Gatta; Giovanni Sparacino; Gianna Maria Toffolo; Piero Amodio
Journal:  Gastroenterology       Date:  2011-07-18       Impact factor: 22.682

Review 6.  Education and the prevalence of dementia and Alzheimer's disease.

Authors:  R Katzman
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

Review 7.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

8.  Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.

Authors:  P Amodio; F Del Piccolo; P Marchetti; P Angeli; R Iemmolo; L Caregaro; C Merkel; G Gerunda; A Gatta
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

9.  The cognitive profile of depressed patients with cirrhosis.

Authors:  Charmaine A Stewart; Felicity T B Enders; Mary M Mitchell; Donna Felmlee-Devine; Glenn E Smith
Journal:  Prim Care Companion CNS Disord       Date:  2011

10.  Subclinical hepatic encephalopathy impairs daily functioning.

Authors:  M Groeneweg; J C Quero; I De Bruijn; I J Hartmann; M L Essink-bot; W C Hop; S W Schalm
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

View more
  17 in total

1.  Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans.

Authors:  Thomas K Burroughs; James B Wade; Michael S Ellwood; Andrew Fagan; Douglas M Heuman; Michael Fuchs; Jasmohan S Bajaj
Journal:  Dig Dis Sci       Date:  2018-01-08       Impact factor: 3.199

Review 2.  Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes.

Authors:  Mary J Thomson; Anna S Lok; Elliot B Tapper
Journal:  Liver Int       Date:  2018-06-19       Impact factor: 5.828

3.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

4.  Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests.

Authors:  Elliot B Tapper; Neehar D Parikh; Akbar K Waljee; Michael Volk; Noelle E Carlozzi; Anna S-F Lok
Journal:  Am J Gastroenterol       Date:  2018-03-13       Impact factor: 10.864

5.  Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.

Authors:  Elliot B Tapper
Journal:  Hepatology       Date:  2019-05-10       Impact factor: 17.425

6.  Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization.

Authors:  Kavish R Patidar; Leroy R Thacker; James B Wade; Richard K Sterling; Arun J Sanyal; Mohammad S Siddiqui; Scott C Matherly; R Todd Stravitz; Puneet Puri; Velimir A Luketic; Michael Fuchs; Melanie B White; Nicole A Noble; Ariel B Unser; HoChong Gilles; Douglas M Heuman; Jasmohan S Bajaj
Journal:  Am J Gastroenterol       Date:  2014-09-02       Impact factor: 10.864

7.  Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study.

Authors:  Sanath Allampati; Andres Duarte-Rojo; Leroy R Thacker; Kavish R Patidar; Melanie B White; Jagpal S Klair; Binu John; Douglas M Heuman; James B Wade; Christopher Flud; Robert O'Shea; Edith A Gavis; Ariel B Unser; Jasmohan S Bajaj
Journal:  Am J Gastroenterol       Date:  2015-12-08       Impact factor: 10.864

8.  Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients.

Authors:  Katherine C Barboza; Lilian M Salinas; Farhad Sahebjam; Arun B Jesudian; Ilan L Weisberg; Samuel H Sigal
Journal:  Metab Brain Dis       Date:  2016-03-31       Impact factor: 3.584

9.  Minimal Hepatic Encephalopathy and Mild Cognitive Impairment Worsen Quality of Life in Elderly Patients With Cirrhosis.

Authors:  Jasmohan S Bajaj; Andres Duarte-Rojo; Jesse J Xie; Chathur Acharya; James B Wade; Carlos Robles; Leroy R Thacker; Christopher Flud; Andrew Fagan; Mauricio Garcia-Saenz-de-Sicilia; Melanie B White; Megan Kelly; Vy Nguyen; Edith A Gavis; Hugo E Vargas
Journal:  Clin Gastroenterol Hepatol       Date:  2020-03-20       Impact factor: 11.382

10.  Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis.

Authors:  J S Bajaj; D M Heuman; P B Hylemon; A J Sanyal; P Puri; R K Sterling; V Luketic; R T Stravitz; M S Siddiqui; M Fuchs; L R Thacker; J B Wade; K Daita; S Sistrun; M B White; N A Noble; C Thorpe; G Kakiyama; W M Pandak; M Sikaroodi; P M Gillevet
Journal:  Aliment Pharmacol Ther       Date:  2014-03-16       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.